

## UTILITY PATENT APPLICATION TRANSMITTAL

(only for new non-provisional applications under 37 CFR §1.53(b))

Mail Stop Patent Application Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450

I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail in an envelope addressed to Mail Stop Patent Application, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on March 9, 2004 Date of Deposit Transmitted herewith for filing is the patent application under 37 CFR 1.53(b) of: Express Mail No AVENTIS DOCKET NO.: DEAV2003/0023 US NP INVENTORS: BRENDEL, et al. **COMBINATION OF PHENYLCARBOXAMIDES** WITH BLOCKERS OF THE IKR CHANNEL AND THEIR USE FOR THE TREATMENT OF ATRIAL ARRHYTHMIAS APPLICATION ELEMENTS \*Fee Transmittal Form (e.g., PTO/SB/17) (Submit an original and a duplicate for fee processing) 2. Specification Total Pages 48 (preferred arrangement set forth below) - Descriptive title of the Invention - Cross References to Related Applications - Statement Regarding Fed sponsored R & D - Reference to Microfiche Appendix - Background of the Invention - Brief Summary of the Invention - Brief Description of the Drawings (if filed) - Detailed Description - Claim(s) - Abstract of the Disclosure 3. Drawing(s) (35 U.S.C. 113) Total Sheets 2 4. Oath or Declaration Total Pages 2 Newly unexecuted (original or copy) a. b. Copy from a prior application (37 CFR § 1.63(d)) **DELETION OF INVENTOR(S)** i. Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR §§ 1.63(d)(2) and 1.33(b). 5. Power of Attorney Total Pages Newly executed (original or copy) a. Copy from a prior application (37 CFR § 1.63(d)) b. Microfiche Computer Program (Appendix) 6.

7.	Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary)											
	a. Computer Readable Copy											
	b. Paper Copy (identical to computer copy)											
	c. Statement verifying identity of above copies											
	If a CONTINUING Application, check appropriate box, and supply the requisite information:  Continuation Divisional Continuation-in-part of prior application no: , filed , Group/Art Unit , Group/Art Unit , The cross reference has been/will be inserted on page one of the specification).											
$\boxtimes$	This application claims the benefit of U.S. Provisional Application No. 60/492,640, filed August 5, 2003 and claims priority to German Application No. DE10312061.0, filed March 18, 2003. (The cross reference has been/will be inserted on page one of the specification).											
	Incorporation By Reference (useable if filing a continuation/divisional and a copy of the declaration from the prior application is enclosed.)  The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied, is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein.											
	OMP	ANYING APPLICATION PARTS	\$									
7.		Assignment Papers (cover sheet	& document(s))									
8.		37 CFR §3.73(b) Statement (when there is an assignee)										
9.		Verified English Translation Do	cument <i>(if applica</i>	able)								
10.	$\boxtimes$	Information Disclosure Statement (IDS)/PTO-1449	$\boxtimes$	8 Copies of IDS Citations								
11.		Preliminary Amendment										
12.	$\boxtimes$	Return Receipt Postcard (MPEI (Should be specifically itemized	•									
13.		*Small Entity Statement(s) (PTO/SB/09-12)		Statement filed in prior application, Status still proper and desired								
14.	$\boxtimes$	Certified Copy of Priority Document(s) – DE10312061.0 of March 18, 2003  (if foreign priority is claimed)										
15.	$\boxtimes$	Other: EPAVE – Application Data Sheet										
COF	RRES	PONDENCE ADDRESS										
$\boxtimes$	Cust	omer Number or Bar Code Label	005487									
			(Insert Customer No. or Attach bar code label here)									
	1.1.07											
			Ronald G. Port	Reg. No. 26,969								
			Attorney/Agent									

Aventis Pharmaceuticals Inc.
Patent Department
Route #202-206 / P.O. Box 6800
Bridgewater, New Jersey 08807-0800
Telephone (908) 231-4656
Telefax (908) 231-2626

Aventis Docket No. DEAV2003/0023 US NP

PTO/SB/17 (01-03)
Approved for use through 04/30/2003. OMB 0651-0032
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

re required to respond to a collection of information unless it displays a valid OMB control number Complete if Known

(\$) 770.00

FEE TRANSMITTAL
for FY 2004
Patent fees are subject to annual revision.

Applicant claims small entity status. See 37 CFR 1.27

TOTAL AMOUNT OF PAYMENT

**Application Number** Not Yet Known Filing Date Herewith BRENDEL First Named Inventor Examiner Name Group / Art Unit Attorney Docket No. **DEAV2003/0023 US NP** 

METHO	FEE CALCULATION (continued)							
Check	Credit Card	Money Other None	3. A	DDITIO	NAL F	EES		
Deposit Acc	count	Order	Large E	ntity	Small E	ntity		
Deposit	<u> </u>		Fee	Fee	Fee	Fee	•	
Account Number		18-1982	Code	(\$)	Code	(\$)	Fee Description	Fee Paid
Deposit Account	Avent	is Pharmaceuticals Inc.					. 55 2555.1545.1	
Name			1051	130	2051	65	Surcharge - late filing fee or oath	
		prized to: (check all that apply)	1052	50	2052	25	Surcharge - late provisional filing fee or cover sheet	
<del> </del>	(s) indicated below	w   Credit any overpayments  during the pendency of this application	1053	130	1053	130	Non-English Specification	
	1012	2,520	1812	2,520	For filing a request for reexamination			
	(s) indicated below re-identified depo	w, except for the filing fee sit account	1804	920*	1804	920*	Requesting publication of SIR prior to Examiner action	
		LCULATION	1805	1,840*	1805	1,840*	Requesting publication of SIR after Examiner action	
1. BASIC FI			1251	110	2251	55	Extension for reply within first month	
Large Entity Fee Fee	Small Entity Fee Fee	Fee Description Paid	1252	420	2252	205	Extension for reply within second month	
Code (\$)	Code (\$)		1232	420		203	Extension or reply within second monar	
1001 770	2001 375	Utility filing fee 770	1253	950	2253	465	Extension for reply within third month	
1002 340	2002 165	Design filing Fee	1254	1,480	2254	725	Extension for reply within fourth month	
1003 530	2003 260	Plant filing fee	1255	2,010	2255	985	Extension for reply within fifth month	
1004 770	2004 375	Reissue filing fee	1401	330	2401	160	Notice of Appeal	
1005 160	2005 80	Provisional filing fee	1402	330	2402	160	Filing a brief in support of an appeal	
1 .	1403	290	2403	140	Request for oral hearing			
2. EXTRA C	1451	1,510	1451	1,510	Petition to institute a public use proceeding			
1		Fee Extra from Fee	1452	110	2452	55	Petition to revive - unavoidable	, ,
1 _		Claims below Paid	ł					
Total Claims 1	-20**=	x =	1453	1,330	2453	650	Petition to revive - unintentional	
Independent 1	- 3**=	x =	1501	1,330	2501	650	Utility issue fee (or reissue)	
Claims			1502	480	2502	235	Design issue fee	
Multiple Depende	ent	=	1503	640	2503	315	Plant issue fee	
l			1460	130	1460	130	Petitions to the Commissioner	
Large Entity Fee Fee	Small Entity Fee Fee	<del>-</del>	1807	. 50	1807	50	Petitions related to provisional applications	
Code (\$)	Code (\$)	Fee Description					••	
1202 18	2202 9	Claims in excess of 20	1806	180	1806	180	Submission of Information Disclosure Stmt	
1201 86	2201 42	Independent claims in excess of 3	8021	40	8021	40	Recording each patent assignment per property (times number of properties)	
1203 290	2203 140	Multiple dependent claim, if not paid	1809	770	2809	375	Filing a submission after final rejection (37 CFR § 1.129(a))	
1204 86	2204 42	**Reissue independent claims over original patent	1810	770	2810	375	For each additional invention to be examined (37 CFR § 1.129(b))	
1205 18	2205 9	**Reissue claims in excess of 20 and over original patent	1801	770	2801	375	Request for Continued Examination (RCE)	
			1802	900	1802	900	Request for expedited examination of a design application	
	SUBTOT	AL (2) (\$)0.00	Other fee	(specify)			***************************************	
**or number pre	viously paid, if gr	*Reduce	d by Basic	Filing Fee	e Paid	SUBTOTAL (3) (\$)		

SUBMITTED BY Complete (If applicable) Registration No. Name (Print/Type) Ronald G. Ort, Reg. No. 26,969 26,969 Telephone (908) 231-4656 (Attorney/Agent) March 8, 2004 Signature Date

> WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

This collection of information is required by 37 CFR 1.17 and 1.27. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Alexandria, VA 22313. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 23313.1450. VA 22313-1450.